NKF advises PolyPeptide on its EUR 111m RCF
NKF advised PolyPeptide on its inaugural EUR 111 million three-year revolving credit facility with Credit Suisse, Danske Bank and Zürcher Kantonalbank as mandated lead arrangers. The RCF includes an uncommitted increase option in an amount of EUR 40 million and is complemented by the extension of the existing CHF 40 million credit facility granted by Draupnir Holding B.V., PolyPeptide’s majority shareholder. The RCF will allow the company to refinance its existing borrowings from banks as well as to finance its working capital and capital expenditure requirements to support its planned business growth.
The Group with its consolidated subsidiaries is a focused Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. Dating back to 1952, PolyPeptide today runs a global network of six cGMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares are listed on SIX Swiss Exchange.
The Niederer Kraft Frey team was led by M&A/finance partner Philip Spoerlé (pictured left), working with associate Selim Lötscher (pictured right, M&A/finance) and partner Markus Kronauer (tax).
